Publications - FIDMAG, Fundation for research

COOKIES USE
We use necessary system cookies for the correct functioning of the website and optional Google Analytics cookies to obtain visit statistics. +info

Cookies config

Necessary

The necessary cookies are absolutely essential for the website to work properly. This category only includes cookies that guarantee basic website security and functionality. These cookies do not store any personal information.

Name	Proveedor	Propiedad	Finalidad	Caducidad
_GRECAPTCHA	google.com	Own	provide antispam protection with the reCaptcha service	6 months
cc_cookie_accept	fidmag.org	Own	Usada per confirmar que l'usuari ha confirmat / refusat les cookies (i quins tipus accepta)	1 any
WEB_SESSION	fidmag.org	Own	Cookie técnica: cookie de sessió PHP. Guarda l'id de sessió d'usuari.	al acabar la sessió

Analisys

Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information on meters, the name of visitors, the percentage of bounces, the font of the traffic, etc.

Name	Proveedor	Propiedad	Finalidad	Caducidad
_ga	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: Identifica els usuaris i proporciona informació sobre com els usuaris troben la pàgina web i com la utilitzen per a realització d'Informes estadístics	2 anys
_gat_gtag_UA_141706552_1	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: Tracking per part de google per google analytics	1 minut
_gid	Google Analytics	From third parties	Cookie d'anàlisi o mesurament: S'usa per limitar el percentatge de sol·licituds	24 hores

Configure Reject all Accept

Home
> Research

Back to results

FI
2.467

22954905

2012 Psychiatry Research

One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, Dueñas R, Alvarez E.

Limited service to collaborators of the network of Sisters Hospitalarias Centers. You will receive a message in your email with a link to download this article.

Abstract

The aim of this study was to compare the 12-month effectiveness of several second-generation antipsychotic drugs, with that of haloperidol in never-treated patients with first-episode psychosis. In total, 114 patients without life time exposure to any psychotropic medication were randomized to haloperidol, olanzapine, risperidone, quetiapine or ziprasidone. Primary outcome was time to all-cause discontinuation. Secondary outcomes included discontinuation rates and symptom change as measured by the Positive and Negative Syndrome Scale (PANSS). The overall discontinuation rate 64%. At 12 months, the proportion of patients discontinuing treatment was 40.0% for olanzapine, 56.5% for quetiapine, 64.0% for risperidone, 80.0% for ziprasidone and 85.7% for haloperidol. Mean time to antipsychotic discontinuation was higher in patients randomized to second-generation antipsychotics than in those taking haloperidol. Significantly lower discontinuation was noted in patients on olanzapine than on haloperidol, or ziprasidone. Our results suggest that olanzapine might lead to longer treatment continuation in treatment naïve FEP patients than haloperidol and, possibly ziprasidone. Global psychopathology was significantly less reduced by haloperidol than with each individual SGA in this earliest phase of treatment.